Quick Answer
DNA X, Inc. reported Stockholders Equity of -$5.70 million for fiscal year 2024.
DNA X, Inc. Stockholders Equity — Annual History
| Fiscal Year | Stockholders Equity | YoY Change |
|---|---|---|
| 2024 | -$5.70M | -125.5% |
| 2023 | $22.37M | +11.6% |
| 2022 | $20.05M | +7.6% |
| 2021 | $18.63M | -34.4% |
| 2020 | $28.41M | +11.3% |
| 2019 | $25.52M | +397.7% |
| 2018 | $5.13M | +105.7% |
| 2017 | -$89.91M | — |
Quarterly Stockholders Equity
| Quarter Ending | Stockholders Equity | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | -$701.0K | -104.6% | +47.5% |
| June 30, 2025 | -$1.33M | -107.6% | -23.6% |
| March 31, 2025 | -$1.08M | -105.4% | +81.1% |
| December 31, 2024 | -$5.70M | -125.5% | -137.1% |
| September 30, 2024 | $15.35M | -33.6% | -12.2% |
| June 30, 2024 | $17.47M | -19.3% | -11.9% |
| March 31, 2024 | $19.84M | -4.1% | -11.3% |
| December 31, 2023 | $22.37M | +11.6% | -3.2% |
- DNA X, Inc. showed a decrease of -125.5% in Stockholders Equity compared to the prior fiscal year.
- Over the 2017–2024 period, DNA X, Inc.’s stockholders equity has grown by 93.7% (from -$89.91 million to -$5.70 million).
- The most recent figure is from DNA X, Inc.’s fiscal year 2024 report (Form 10-K), filed with the SEC on March 31, 2025.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: